DMPK Lead (PBPK Specialist), London, Lausanne

Essential:

PhD in either Pharmaceutical Science, Pharmacy, Chemistry, or another relevant subject.

5+ years’ professional as a DMPK Lead, solving DMPK-related problems in preclinical development with a track record of working collaboratively to deliver regulatory-ready FIH packages.

Practical experience in setting up automated PBPK workflows.

Practical experience in using PBPK to support preclinical development.

Practical experience developing DMPK and quantitative pharmacology packages to support early clinical development, including authoring and reviewing regulatory documents, ideally in oncology.

At Isomorphic Labs, DMPK Leads drive the DMPK strategy of drug discovery and development projects to deliver high quality clinical candidates whilst using and contributing to the optimisation of state-of-the-art computational and AI ADME models.

As part of the Drug Design and Medical Research team and through close collaboration with the Technology teams, you will support the business alongside world leading AI/ML Drug Design Platform teams. You will collaborate to deliver scientific expertise and strategic direction to drive both improvements in the Platform and apply this to real drug design projects. You use your expertise in PBPK modelling to make data integration a powerful tool to accelerate drug design and preclinical development.

If you are a skilled and ambitious scientist looking to take the next step in your career, joining the Isomorphic Labs now will lift you out of your comfort zone and provide you with an amazing opportunity for personal growth and development.

Define Iso’s PBPK strategy leading to fit for purpose models that drive drug design and accelerate accelerate preclinical development.

Design and implement stage-appropriate development DMPK strategies with AI-first approach, integrate the quantitative pharmacology and overall project strategies.

The DMPK and Quantitative Pharmacology team, part of the Preclinical Development group, accelerates the delivery of high quality drug candidates by developing innovative and creative AI-first solutions. By applying our domain expertise and through collaboration with the entirety of our world-class drug discovery disciplines and ML researchers, we ensure that drug-like properties are at the heart of our drug design engine. We shape the development of state-of-the-art ADME and toxicology predictive models. We rethink drug discovery from Hit ID to first-in-human (FIH) trials by optimising the context of use of these models.